Akari Therapeutics, Plc

Akari Therapeutics, Plcverified

AKTX

Price:

$0.985

Market Cap:

$11.96M

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.[Read more]

Industry

Biotechnology

IPO Date

2014-01-06

Stock Exchange

NASDAQ

Ticker

AKTX

The Enterprise Value as of December 2024 (TTM) for Akari Therapeutics, Plc (AKTX) is 10.72M

According to Akari Therapeutics, Plc’s latest financial reports and current stock price. The company's current Enterprise Value is 10.72M. This represents a change of -48.79% compared to the average of 20.93M of the last 4 quarters.

Akari Therapeutics, Plc (AKTX) Historical Enterprise Value (quarterly & annually)

How has AKTX Enterprise Value performed in the past?

The mean historical Enterprise Value of Akari Therapeutics, Plc over the last ten years is 655.16M. The current 10.72M Enterprise Value has changed 63.57% with respect to the historical average. Over the past ten years (40 quarters), AKTX's Enterprise Value was at its highest in in the September 2021 quarter at 1.50B. The Enterprise Value was at its lowest in in the March 2018 quarter at 4.29M.

Quarterly (TTM)
Annual

Average

655.16M

Median

272.70M

Minimum

11.43M

Maximum

2.40B

Akari Therapeutics, Plc (AKTX) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Akari Therapeutics, Plc Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 194.84%

Maximum Annual Enterprise Value = 2.40B

Minimum Annual Increase = -94.63%

Minimum Annual Enterprise Value = 11.43M

Quarterly (TTM)
Annual
YearEnterprise ValueChange
202311.43M-29.01%
202216.09M-70.75%
202155.02M23.96%
202044.39M68.70%
201926.31M-94.63%
2018490.37M-54.04%
20171.07B-34.30%
20161.62B-32.39%
20152.40B194.84%
2014814.73M147.23%

Akari Therapeutics, Plc (AKTX) Average Enterprise Value

How has AKTX Enterprise Value performed in the past?

The current Enterprise Value of Akari Therapeutics, Plc (AKTX) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

27.51M

5-year avg

30.65M

10-year avg

655.16M

Akari Therapeutics, Plc (AKTX) Enterprise Value vs. Peers

How is AKTX’s Enterprise Value compared to its peers?

Akari Therapeutics, Plc’s Enterprise Value is less than Armata Pharmaceuticals, Inc. (136.74M), less than Anebulo Pharmaceuticals, Inc. (32.31M), greater than Scopus BioPharma Inc. (-111950.00), greater than Processa Pharmaceuticals, Inc. (1.19M), less than Salarius Pharmaceuticals, Inc. (0), greater than Axcella Health Inc. (-678147.00), greater than Magenta Therapeutics, Inc. (-14986000.00), greater than Histogen Inc. (-114170976.00), greater than Pulmatrix, Inc. (-4487565.00), less than Capricor Therapeutics, Inc. (11.75M), less than Diffusion Pharmaceuticals Inc. (603.95M), greater than Soleno Therapeutics, Inc. (8.02M), less than Oncorus, Inc. (1.99B), less than Sonnet BioTherapeutics Holdings, Inc. (42.71M), greater than Landos Biopharma, Inc. (-1862852.00), less than null (42.62M),

Build a custom stock screener for Akari Therapeutics, Plc (AKTX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Akari Therapeutics, Plc using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Akari Therapeutics, Plc (AKTX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Akari Therapeutics, Plc or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Akari Therapeutics, Plc's Enterprise Value?

What is the highest Enterprise Value for Akari Therapeutics, Plc (AKTX)?

What is the 3-year average Enterprise Value for Akari Therapeutics, Plc (AKTX)?

What is the 5-year average Enterprise Value for Akari Therapeutics, Plc (AKTX)?

How does the current Enterprise Value for Akari Therapeutics, Plc (AKTX) compare to its historical average?